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The authors represent a cooperative group of 15 institutions that examined the feasibility of using metabolic fea­
tures observed in vivo with ‘H-magnetic resonance (MR) spectroscopy to characterize brain tumors o f  the glial type. 
The institutions provided blinded, centralized MR spectroscopy data processing along with independent central review 
of MR spectroscopy voxel placement, composition and contamination by brain, histopathological typing using current 
World Health Organization criteria, and clinical data, Proton 'H-MR spectroscopy was performed using a spin-echo 
technique to obtain spectra from 8-cc voxels in the tumor and when feasible in the contralateral brain. Eighty-six cases 
were assessable, 41 of which had contralateral brain spectra. Glial tumors had significantly elevated intensities of 
choline signals, decreased intensities of creatine signals, and decreased intensities of N- acetyl asp art ate compared to 
brain. Choline signal intensities were highest in astrocytomas and anaplastic astrocytomas, and creatine signal intensi­
ties were lowest in glioblastomas. However, whether expressed relative to brain or as intratumoral ratios, these meta­
bolic characteristics exhibited large variations within each subtype of glial tumor. The resulting overlaps precluded 
diagnostic accuracy in the distinction of  low- and high-grade tumors. Although the extent of contamination of the ]H- 
MR spectroscopy voxel by brain had a marked effect on metabolite concentrations and ratios, selection o f  cases with 
minimal contamination did not reduce these overlaps. Thus, each type and grade of tumor is a metabolically hetero­
geneous group. Lactate occurred infrequently and in all grades. Mobile lipids, on the other hand, occurred in 41%  of 
high-grade tumors with higher mean amounts found in glioblastomas. This result, coupled with the recent demonstra­
tion that intratumoral mobile lipids correlate with microscopic tumor cell necrosis, leads to the hypothesis that mobile 
lipids observed in vivo in EH-MR spectroscopy may correlate independently with prognosis of individual patients.
K ey W ords • b r a in  neoplasm  • glioma • m agnetic  resonance spectroscopy • lip ids • 
m etabolite
T h e  prognostic significance of histopathological and 
molecular biological factors in brain tumors is of 
interest because these factors are potentially able 
to  guide clinical management decisions.32 The association 
betw een poor survival of patients with glial tumors and 
g lucose hypermetabolism determined by positron emis­
s io n  tomography (PET) i>2^ 25<44'56 raised interest in examin­
in g  correlations between visualizable in vivo metabolic 
features and prognosis in brain tumors. Recently, proton
]H-nuclear magnetic resonance (NMR) spectroscopy has 
also been applied to study metabolic aspects of brain 
tumors. Nuclear magnetic resonance spectroscopy uses 
radiofrequency excitation in the presence o f a m agnetic 
field to obtain signals from naturally occurring 'H  nuclei 
to identify and quantitate metabolites. The m ost com ­
monly acquired 'H-NMR spectra of brain have three 
major peaks, one containing primarily signals from  cho­
lines (choline, phosphorylcholine, and glycerophospho-
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rylcholine), one primarily from creatines (creatine and 
phosphocreatine), and one primarily from acetyl aspar­
tate (NAA), In disease, signals from lactate and mobile 
lipids may also be observed.
Studies of extracts of surgical specimens of human as­
trocytic tumors using ]H-NM R spectroscopy indicated 
an increase in the ratio of cholines to creatines, and a 
decrease in the ratio of NAA to creatines, with increas­
ing histopathological grades of malignancy.16,45’61 Studies 
in patients using !H-NMR spectroscopy, referred to as MR 
spectroscopy, indicated sim ilar correlations between 
metabolic features in vivo and the histopathological 
grades of astrocytic tumors.4’11’14’21,32,43’57’58’61 Other MR 
spectroscopy studies indicated that lactate is more likely 
to be present in high- than in low-grade tumors4,14,15'20’21 
and that the amount of lactate may correlate with the 
extent of hypermetabolic glucose consumption shown in 
PET 2,14,22 In a recent study, lipids were recognized in vivo 
in 23% of spec t o  from 48 gliomas and the authors sug­
gested that these lipids occur with higher incidence in 
tumors of higher histopathological grade;43 this agrees 
with the finding in intact surgical specimens that higher 
grade astrocytic tumors contain mobile lipids, the amounts 
of which correlate with the amount of microscopic cellu­
lar necrosis.31
In all published studies, metabolic signal intensities had 
large coefficients of variation within, and overlaps be­
tween, histopathological grades of glial tumors. More­
over, trends in metabolic changes among different grades 
were inconsistent. For example, in some studies the cho­
line/creatine ratio did not progressively increase with in­
creasing grade,11,14,32 and in some the level of NAA did not 
progressively decrease with increasing grade but was 
higher in high grades than in intermediate ones or in inter­
mediate grades compared to low ones 4,11,32,43,57,61 The vari­
ations and overlaps have precluded diagnostic use of 1H- 
M R spectroscopy to distinguish grades of glial tumors. 
Factors that may contribute to this and to different results 
from different studies include: nonuniformity of histo­
pathological grading systems; spatial variations in grading 
within a tumor; nonuniformity of techniques used to local­
ize ^ -N M R  spectra to the region of interest; and variable 
attempts to avoid contamination of spectra by metabolites 
from edematous brain and obvious non viable regions of 
tumors. Different ^ -M R  spectroscopy acquisition param­
eters, in particular, different echo and repetition times, 
modulate metabolite signal intensities in different ways. 
Finally, the identification and quantitation of lipids in vivo 
requires methods that permit distinction between intratu- 
moral lipids and contaminant lipid signals from the skull 
or scalp and between lipid and lactate signals that overlap 
one another.
To attempt to overcome some of these limitations, ac­
crue a sizable number of patients with different grades of 
glial tumors in a short time, and define more accurately 
the potential of in vivo single-voxel !H-M R spectroscopy 
to characterize primary brain tumors, we organized a 
cooperative group consisting of 15 institutions using iden­
tical acquisition techniques in similar clinical instruments. 
Our study, preliminary accounts of which have been pre­
sented elsewhere,39,40 provides blinded uniform MR spec­
troscopy data processing at a central location, uniform
histopathological typing, uniform criteria for case selec­
tion, and quantitation of lipids and lactate.
Clinical Material and Methods
Establishment o f the Cooperative Group and Technical 
Quality-Control Procedures
Institutional eligibility required: 1) a Siemens 1.5-tesla 
magnetic field-strength Magnetom SP with A2.3 software 
and a circularly polarized head coil; 2) a standard 'H-MR 
spectroscopy protocol; and 3) the ability to meet quali- 
ty-control criteria established in a preceding study. In 
the preceding study spectra were obtained using a spin- 
echo technique7 from nominal 8-cc voxels in parietooc­
cipital lobes and basal ganglia of six volunteers at each of 
38 institutions.53 Technical quality-control procedures per­
formed on phantoms and volunteers included calibration 
of transmitter adjustment, global shimming to adjust for 
static Bo inhomogeneity, eddy current adjustments, local 
shimming to adjust for local static and dynamic Bo inho­
mogeneity, and calibration of water suppression. The first 
criterion for acceptance of MR spectroscopy data from an 
individual case included absence of any artifacts resulting 
from miscalibration or misadjustment of shimming, eddy- 
current correction, or water suppression, which interfere 
with analysis of metabolite intensities. The second criteri­
on was an adequate signal-to-noise ratio to permit repro­
ducible peak area integration. The third criterion, applica­
ble to NMR spectra from voxels placed near the skull, was 
absence of contaminating lipid signals, which overlap or 
distort other peaks in the spectrum.
Patient Selection
Patients of any age with newly diagnosed or recurrent 
primary brain tumors of the glial subtype were examined. 
The initial criteria for inclusion in this study were: 1) 
acceptable quality of the spectrum; 2) evidence on MR 
imaging of a tumor occupying at least half the volume of 
the 8-cc MR spectroscopy voxel; and 3) histological con­
firmation of the diagnosis at some time in the course of the 
disease. We accepted recurrent cases if they had adequate 
objective clinical evidence of recurrence of tumor includ­
ing rebiopsy and/or diagnostic MR imaging and compu­
terized tomography scans. We included four cases with a 
clinical diagnosis of astrocytoma that was made without a 
biopsy because they had typical clinical and MR imaging 
features and a biopsy could have caused unnecessary 
brainstem damage.
Data Flow, Database, and Evaluation
Magnetic resonance imaging, histological, clinical, and 
demographic data were submitted to Fox Chase Cancer 
Center for central review. The algorithm by which cases 
were evaluated and included or excluded from analysis is 
summarized in Fig. 1.
Clinical MR imaging studies were required to meet the 
following criteria: 1 ) images had to be produced in at least 
two planes to permit accurate definition of the MR spec­
troscopy voxel placement; 2) images had to be sufficient 
to permit an independent outside observer to assess the 
presence of a solid, apparently viable tumor and the voxel
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F ig . 1. Evaluation algorithm used in the study, MRI = magnet­
ic resonance imaging; MRS = magnetic resonance spectroscopy; 
Q.C. = quality control.
placem ent relative to it; and 3) images had to be submit­
ted  for central review. The compositions of the M R spec­
troscopy voxels were assessed independently using all 
available MR imaging studies and expressed as fractions 
o f  solid tumor, edematous brain, nonedematous brain, 
liquefaction necrosis, cystic hemorrhagic necrosis, simple 
cysts, surgical cystic defects, ventricle, and extramed- 
ullary tissue (for example, skull). The region of solid tu­
m or was often readily apparent in a combination of stan­
dard Tj- and T2-weighted images. However, in accordance 
w ith recent experience,19 we found that for many astrocyt­
ic tumors and for most tumors that recurred after prior 
treatment, contrast enhancement was necessary to define 
the location and extent of apparently viable tumor and to 
differentiate it from cystic necrosis and edematous brain. 
T he ratio of the volume of solid tumor to that of solid 
tum or plus brain (tumor/tumor + brain) was calculated 
and  is referred to as the “tumor fraction.” In this expres­
sion, the term “tumor” is used only to describe solid 
tumor, not cystic or necrotic regions, and the term “brain” 
includes edematous and nonedematous brain. We accept­
ed any case with an estimated tumor fraction in the 8-cc
MR spectroscopy voxel greater than 0.5, because we did 
not know a priori the extent to which contamination o f the 
spectrum with metabolites in brain would affect the abili­
ty of ]H-MR spectroscopy to characterize tumors.
Histopathology reports were reviewed independently at 
Fox Chase Cancer Center to ascertain the diagnosis and to 
confirm typing of glial tumors according to the current 
World Health Organization (WHO) classification:27 as­
trocytic tumors, oligodendrogliomas, and ependymomas. 
Astrocytic tumors were subclassified according to in ­
creasing grade o f malignancy as astrocytoma (AS), ana­
plastic astrocytoma (AA), and glioblastoma m ultiform e 
(GBM). In approximately two-thirds of the cases, pathol­
ogists used this classification explicitly. In the rem ain­
der, the previous WHO or other classifications that used 
numerical grading (I-IV) were used. However, typical 
GBM and typical low-grade AS were readily identified. 
Thus, less than 10% of astrocytic tumors originally had 
been designated “Grade III” or “Grade III—IV” and re ­
quired reassignment to current WHO typing. If there was 
any necrosis or vascular proliferation within tum or-con­
taining regions in the microscopic description, the case 
was designated GBM. Four cases in which current W HO 
typing was not used and whose microscopic description 
was inadequate to permit independent assignment were 
excluded from further analysis.
Recurrent tumor cases were evaluated to ascertain inde­
pendently the strength of the evidence for recurrence 
and, in cases previously treated, the ability to separate 
the region of tumor from regions of radiation or surgical 
damage. Information used to make these judgm ents in ­
cluded the MR imaging studies (with and without contrast 
enhancement), computerized tomography scans, and re ­
cently repeated biopsies. If objective evidence for recur­
rent tumor could not be ascertained, the case was exclud­
ed from further analysis.
Proton lH-Magnetic Resonance Spectroscopy
Scout MR images using fast low-angle shot (FLA SH )18 
were obtained in two or three planes through the brain to 
define the region of placement of 8-cc M R spectroscopy 
voxels. Voxels were placed to maximize their content of 
viable tumor. Necrotic or cystic regions of tumors were 
avoided when possible but were included in the voxel if 
necessary to limit brain contamination. Wherever feasible, 
'H-NMR spectra were obtained both from the tum or and 
the mirror-image region in the contralateral brain. Global 
and localized shimming on the water proton was per­
formed to obtain less than 25 Hz and 10 Hz full width at 
half-maximum, respectively, from brain. Spectra were 
localized using the spin-echo method7 along with chem i­
cal shift selective water suppression.17 A single-voxel 
method, rather than multivoxel chemical shift im aging, 
was selected because of the feasibility of implementation 
in clinical imagers at multiple institutions. The spin-echo 
method was selected based partly because of its signal-to- 
noise advantage over the stimulated echo m ethod .37 The 
advantages and limitations of this method have been dis­
cussed.48,55 Different regions of the spectrum have signals 
emitting from slightly different voxels: those of cholines 
at 3.2 ppm are from a voxel whose dimensions are each 
shifted approximately 10% relative to those of lipids at
7. Neurosurg. /  Volume 84 /  March, 1996 451
W. G. Negendank, et al.
CREATINES
4.0 3.5
CHOLINES
TUMOR
CREATINES
CHOUN£S
CREATINES
3.0
H-
2.5 2.0 1.5 1.0
-f
0.5
CREATINES
4.0 3.5 3.0
ppm
2.5 2.0
ppm
1.5 1.0 0.5
Fra. 2. Magnetic resonance (MR) spectroscopy voxel locations and LH-MR spectra in a patient with an astrocytic 
tumor in the right parietal lobe. Upper Left: A  T2-weighted MR image showing the position of the 2 X 2 X 2 cm voxel 
centered in the tumor. Upper Right: A T3-weighted M R image showing the position of die 2 X 2 X 2 cm voxel in the 
contralateral brain. Lower Left and Right: Charts displaying ’H-MR spectra from the tumor (lower left) and the con­
tralateral brain (lower right).
0.9 ppm. Chemical shift dispersion reduces the effective 
voxel size for lactate to 5.6 ml when the nominal voxel 
size for singlet resonances is 8 ml. This, along with imper­
fections in rectangular slice profiles and effects of multi­
ple quantum coherences by variations in pulse angles, 
results in approximately a 50% reduction in sensitivity of 
the spin-echo method for lactate.
Two-hundred fifty-six acquisitions were obtained with 
an echo time of 135 msec and a repetition time of 1600 
msec to give a total M R spectroscopy acquisition time of
6.5 minutes. The echo time of 135 msec was used so that, 
relative to the remainder of the spectrum, lactate methyl 
proton signals would be 180° out of phase whereas intra- 
tumoral lipid methylene proton signals (which overlap 
lactate at 1.3 ppm) would be in phase. Phase distortions in 
the water-suppressed !H-NM R spectrum caused by eddy 
currents were removed by taking a nonsuppressed water 
reference signal acquired with the same M R spectroscopy 
sequence and calculating a phase transformation factor, 
permitting one to set the phase angle to zero for each time 
point.28,42 The JH-MR spectroscopy procedure is illustrat­
ed in Fig. 2, in which M R spectroscopy voxel positions 
are overlaid on scout M R images and spectra from tumor 
and brain are shown.
Analysis o f Data From MR Spectroscopy
Digital M R spectroscopy data were submitted for blind­
ed analysis to Siemens, A G  (Erlangen, Germany). Peak 
areas were determined by manual integration using Sie­
mens Numaris software. Peaks were assigned according
to their positions relative to water at 4.7 ppm and metabo­
lite identification in vitro,3126,49 Brain spectra (Fig. 2) con­
tain four peaks: one primarily from the N-trimethyl pro­
tons of choline-containing metabolites at 3.2 ppm, one 
from the //-methyl protons of creatines at 3.0 ppm, a 
smaller one from the methylene protons of creatine at 
3.9 ppm, and one primarily from the methyl protons of 
NAA at 2.0 ppm. N-acetylaspartate is within neurons and 
therefore is decreased whenever the brain is damaged or 
replaced. In tumors the peak around 2.0 ppm may then 
contain larger fractions of metabolites present in con­
centrations normally much lower than that of NAA, 
including N-acetyl-aspartylglutamate, glutamine, gluta­
mate, and 7 -aminobutyiic acid. Therefore, in tumors we 
refer to the “NAA region” rather than to “NAA.”
The MR spectroscopy data are presented in two ways. 
First, the peak area intensity of the signal of each m etabo­
lite in the tumor was expressed as a ratio to the intensity 
of creatines in contralateral brain. Assuming brain cre­
atines to be an appropriate reference and ignoring any 
possible saturation effects, this permits estimation of 
the extent to which metabolite concentrations are altered 
in tumors. Second, peak area intensities of intratumoral 
metabolites were expressed as ratios to one another and 
compared to the same ratios in contralateral brain and in 
other tumor types. Mean ratios were compared between 
groups by nonparametric tests to take into account non­
normal distributions within some of the groups. The 
M ann-W hitney U-test was used for nonpaired group com ­
parisons and the Wilcoxon signed-rank test for paired
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TABLE 1
Selection and exclusion within 113 cases of patients with glial
tumors on MR spectroscopy *
Case Selection No. of Cases
cases with MR spectroscopy data submitted 113
cases excluded from analysis 27
M R  spectrum of poor quality 12
<0.5 tumor/tumor + brain in voxel 11
insufficient histopathological description 4
cases evaluated 86
cases with spectra from contralateral brain 41
* MR = magnetic resonance.
group comparisons. Analysis of variance was used to 
compare metabolite ratios across histopathological grades 
and Fisher’s exact test to compare incidences of lipids and 
lactate in tumor subgroups.
Results
Fifteen institutions studied 113 patients with glial tu­
m ors over approximately 1 year. Application of the eval­
uation algorithm (Fig. 1) resulted in the exclusion of 
27 cases (Table 1). The 86 cases selected for evaluation 
included 75 astrocytic tumors, six oligodendrogliomas, 
and five ependymomas. Of the 19 ASs, five were pilocyt- 
ic, one was a subependymal giant cell, and one a mixed 
oligoastrocytoma. Of the 22 AAs, one was a mixed 
oligoastrocytoma. Diagnoses, demographic data, relevant 
clinical data, and results of independent analysis of MR 
spectroscopy voxel compositions are summarized in Table 
2. Thirteen glial tumors were found in children ( < 1 8  
years old); nine of these tumors were astrocytic and four 
w ere ependymomas. Of 55 newly diagnosed cases, only 
seven patients had had biopsy before MR spectroscopy 
was performed. Of 31 recurrent tumors, 25 had previous­
ly  been treated with radiation therapy.
The effect of voxel contamination on the ratios of the 
levels of cholines, creatines, and the NAA region in astro­
cytic tumors to those of the corresponding metabolites in 
brain  is shown in Fig. 3. As expected, the mean intensity 
o f  the NAA region in tumors relative to that in the con­
tralateral brain decreased progressively with decreasing 
brain contamination. The mean intensity of creatines in 
tumors relative to that in the contralateral brain was slight­
ly reduced, but did not decrease progressively with de­
creasing brain contamination. The mean intensity of 
cholines in tumors relative to that in the contralateral brain 
w as much higher in cases with tumor fractions of 0.7 to 
0.8 or 0.9 to 1.0 than in cases with tumor fractions of 0.5 
to  0.6. Therefore, in subsequent analyses, we included 
only  cases with voxels containing tumor fractions of at 
least 0.7.
The results in Fig. 3 indicate that the concentration 
o f  choline is increased and that of creatine is slightly de­
creased in glial tumors compared to brain. The effect of 
the histopathological grade of the tumor on metabolite 
concentrations, expressed as the ratio of their peak area 
intensities to those of creatines in the contralateral brain, 
is shown in Fig. 4 and statistical comparisons are given in 
the figure legend. The mean intensity of cholines was sig­
TABLE 2
Characteristics o f  86 cases evaluated*
Glial AS AA GBM OD EP
(86 (19 (22 (34 (6 (5
Characteristic cases) cases) cases) cases) cases) cases)
age of patients (yrs)
mean 41 30 43 51 35 14
range 3-75 5-73 3-72 18-75 30-39 4-30
gender
male 51 11 13 21 4 2
female 35 8 9 13 2 3
tumor status
new 55 14 12 21 3 5
recurrent 31 5 10 13 3 0
prior radiation 25 4 9 11 1 0
fraction of tumor in voxel
0.5-0.6 14 5 1 7 1 0
0.7-0 .8 28 3 8 14 1 2
0.9-1.0 44 11 13 13 4 3
* Abbreviations: AA = anaplastic astrocytoma; AS = astrocytoma; EP = 
ependymoma; GBM = glioblastoma multiforme; OD = oligodendroglioma.
nificantly higher in AS and AA compared to brain but not 
significantly higher in GBM compared to brain, The mean 
intensity of creatines was the same in AS as in brain but 
decreased progressively with the increasing histopatho­
logical grade of the astrocytic tumor. The mean intensity 
of the NAA region was decreased in all tumor types.
The results displayed in Fig. 4 indicate that the over­
lap of metabolite signal intensities or of concentrations 
among grades of astrocytic tumors is too great to provide
1.80 • *
1.60 ■ •
1.40«*
1 , 2 0  • •
1.00 ■ -
0 , 0 0  ■ ■
0.60 « *
0.4Û « •
0,20 •  >
0.00 ♦ ♦
Q.5-0.Ó ' 0.7-0.8 ~ 0.9-1.0 
Fraction of Voxel Containing Tumor
Fig. 3. Graph depicting the effect of voxel contamination by 
brain on ratios of metabolite signal intensities in tumors to those in 
contralateral brain. The fractions of tumor within the magnetic res­
onance spectroscopy voxels are indicated. Values are expressed as 
means ±  standard error. CHOL = choline; CR = creatine; NAA = 
Af-acetylaspartatc.
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Fig. 4. Graph displaying the means, standard deviations, and 
scatterplot of cholines, creatines, and N -acetyl aspartate (NAA) 
region in astrocytic tumors expressed as ratios to the creatine peak 
intensities in contralateral brain. AA = anaplastic astrocytomas; 
AS = astrocytomas; B = brain; GB -  glioblastomas multiforme. 
Significance o f  differences (p) compared to brain: for cholines, 
AS 0.0014, AA 0.0002, and GB 0.1905; for creatines, AS 0.9999, 
AA <  0.0001, and GB 0.0001; for N A A  region, AS, AA, and 
GB < 0 .0001 .
any diagnostic accuracy Therefore, we examined the ra­
tios between any two metabolites within the same tumor 
and the results are summarized in Table 3. All major types 
of glial tumors had significantly higher mean choline/ 
creatine and choline/NAA ratios, and a lower mean 
NAA/creatine ratio, compared to brain* Among tumor 
subtypes, AA had a significantly higher mean choline/cre­
atine ratio than AS. However, the variations and overlaps 
among the tumor types remained large.
The spectrum of a tumor containing lactate is shown in 
Fig. 5 left. It appears as a doublet 180° out of phase cen­
tered at 1.3 ppm. The spectrum of a tumor containing
TABLE 3
Comparison o f metabolic ratios in glial tumors to those in 
contralateral brain spectra in unpaired observations*
Choline/Creatine NAA Region/ Choline/NAA
Sample Ratio Creatine Ratio Region Ratio
brain (41 cases) 0.97 ±  0.22 1.78 ±  0.48 0.59 ±  0.23
astrocytoma (14 cases) 2.13 ±  0 .82f 0.78 ±  0.44t 2.52 ±  1.29t
anaplastic astrocytoma 2.82 ±  1.45+t 0.99 ±  0.58f 3.29 ±  2.17t
(21 cases)
glioblastoma multi forme 2.77 ±  1.93*1* 0.89 ±  0.43 f 3.99 ±  3.75t
(27 cases)
oligodendroglioma 5.00 ±  3.96§ 1.03 ±  0.63|| 6.53 ±  6.13**
(4 cases)
ependymoma (5 cases) 2.80 ±  0 .4 9 f t 0.98 ±  0A2U  3.96 ±  3.27**
5)5 Eight tumors exhibited no quantifiable creatines, hence infinitely high 
ratios of cholines or o f NAA region to creatines ate not included in this 
table. Values are expressed as means ±  standard deviations with p values 
for tumors compared to brain based on the M ann-W hitney U-test. NAA 
= //-acetyl aspartate.
t p  <  0.0001; |  p =  0.0264 for anaplastic astrocytoma compared to 
astrocytoma; § p =  0.0009; || p = 0.0358; ** p  = 0.0100; t t  P = 0.0003;
W p = 0.0028.
TABLE 4
Incidence o f lipids and lactate in 86 glial tumors
Total No. Lipids Lactate
Tumor Type of Cases No. (%) No. (%)
astrocytic tumors 75 26 (35) 9(12)
astrocytoma 19 3(16) 4(21)
anaplastic astrocytoma 22 8(36) 1(5)
glioblastoma multiforme 34 15 (44) 4(12)
prior radiation 24 11 (46) 3(13)
no radiation 51 15 (29) 6 ( 12)
oligodendroglioma 6 0 0
ependymoma 5 0 1 (2 0 )
mobile lipids is shown in Fig. 5 right The fatty acyl-CH2 
peak is at 1.3 ppm and the acyl-CH3 peak is at 0.9 ppm. 
Lipid signals from skull or scalp were distinguished from 
intratumoral lipids by: 1) a voxel position near the skull; 
2) similar contamination in the contralateral brain spec­
trum; and 3) anomalous phase errors and/or chemical 
shifts. By these criteria, the small lipid signal at 1.3 ppm 
in the tumor shown in Fig. 2 is assumed to be contamina­
tion from skull or scalp.
The incidences of lipids and lactate in the major tumor 
types are shown in Table 4. Lipids occurred in 41% of 
AAs and GBMs but in only 16% of ASs. These incidences 
may be lower than actual ones because we did not include 
two cases in which it was not possible to separate lipid 
from lactate and 14 cases in which signals in the 0.5 to L7 
ppm region, judged to have resulted only from contami­
nation, could have masked intratumoral lipids or lactate. 
The relation between lipid signal intensity and histopatho- 
logical grade of astrocytic tumors is shown in Fig. 6. The 
mean level of 1.3 ppm/choline in GBMs with lipids 
(3.2 ±  3.1 standard deviation (SD)) was higher than those 
in AAs with lipids (1.8 ±  1.7) and in ASs with lipids 
(0.5 ±  0.4; p -  0.0503). Lactate was detected in only nine 
of the 75 astrocytic tumors and in one of the five ependy­
momas, and occurred in low- as well as high-grade tumors 
(four ASs, one AA, and four GBMs).
New and recurrent astrocytic tumors had identical mean 
choline/creatine (p = 0.90) and NAA/creatine ratios (p = 
0.92). The 25 tumors treated with prior radiation had a 
mean choline/creatine ratio of 2.5, not unlike that of non­
radiated tumors (2.6; p = 0.77). The incidence of lactate 
was the same in radiated and nonradiated astrocytic tu­
mors (Table 4). Lipids occurred more frequently in radiat­
ed tumors (0.46) than in nonradiated ones (0.29), but this 
difference was not significant (p = 0.198) and may reflect 
the higher grade of recurrent tumors. Therefore, metabol­
ic changes associated with radiation did not confound our 
results, possibly because of the effort made to ensure the 
presence of viable tumor in the MR spectroscopy voxel in 
all cases.
Discussion
This study shows that a multiinstitutional cooperative 
trial of !H-MR spectroscopy is feasible. It enabled accru­
al of a large number of cases in a short period of time, 
approximately 1 year for most of the institutions. Because 
this was one of the first attempts to perform such a trial,
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Fig. 5. Examples of spectra with lipids or lactate. Left.: Lac- 
tate-CH, appears as an inverted doublet at 1.3 ppm (asterisk). 
Right: Lipids with the dominant fatty acyl-CH2 peak at 13  ppm 
and the -CH3 at 0.9 ppm (asterisks).
ours has been a learning experience and the clinical qual­
ity  assurance procedures (Fig. 1) were applied retrospec­
tively. This and our insistence on independent, central re­
view  of imaging, histopathological reporting, and clinical 
da ta  may account for the relatively large number of cases 
excluded from analysis. However, if quality-assurance cri­
teria  established during this study were applied prospec- 
tively rather than retrospectively and if voxel sizes small­
e r  than 8 cc were permitted, it should be possible to 
increase the number of cases that could be evaluated.
The major observations of this study are: 1) elevated 
m ean signal intensities of cholines, and decreased intensi­
ties of creatines and the NAA region in glial tumors com­
pared to contralateral brain; 2) intratumoral lipids in 41% 
o f higher grade (AA and GBM) astrocytic tumors, the 
m ean amount higher in GB than AA; and 3) infrequent 
occurrence of lactate with no relation to histopathological 
grade. The elevated choline/creatine ratio in primary 
glial brain tumors in general, observed here and in some 
studies in the literature (discussed below), is caused by 
increased signal intensities of cholines and decreased 
signal intensities of creatines compared to brain. Con­
tamination of the MR spectroscopy voxel by brain has a 
marked effect on metabolite intensities and ratios, but 
selection of cases in which the MR spectroscopy voxel 
contained a relatively low amount (<  30%) of contamina­
tion did not overcome the large variations within, or over­
laps between, the three histopathological grades o f astro­
cytic tumors.
The mean metabolite ratios in contralateral brain (0.97 
fo r choline/creatine and 1.78 for NAA/creatine) are simi­
lar to those in the normal volunteer study53 to which each 
o f  the institutions in our trial contributed spectra from a 
designated position in the parietooccipital lobe (0,81 for 
choline/creatine and 2.16 for NAA/creatine) and the 
caudate nucleus (0.95 for choline/creatine and 1.87 for 
NAA/creatine). The coefficients of variations are also 
similar to those observed in the volunteer study: 23% 
for choline/creatine compared to 19% in parietooccipital 
lobes and 20% in caudate nuclei; and 27% for NAA/crea- 
line compared to 19% in parietooccipital lobes and 29% in 
caudate nuclei. This result indicates that overall technical 
quality control established in the volunteer study was
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Fig. 6. Graph showing lipids in astrocytic tumors, expressed 
as the ratio of intensity of the 1.3 ppm methylene peak to that of 
cholines (Choi). A A = anaplastic astrocytomas; AS = astrocy­
tomas; GBM = glioblastomas multiforme.
maintained by the institutions in this patient study. 
Therefore, the much greater variations of choline and cre­
atine metabolite ratios observed in glial tumors may be 
the result o f greater metabolic differences between them. 
Each type and grade of tumor appears to represent a meta- 
bolically heterogeneous group.
The microscopic or biological basis for metabolic het­
erogeneity within solid or apparently viable tumor is not 
clear Some astrocytic tumors are not distinct solid mass­
es but rather infiltrate brain tissue27 that produces the 
NAA signals observed even when little evident brain is 
within the voxel (Fig. 3), Many benign ASs contain foci 
of anaplastic cells,50,34 and GBMs containing foci of ASs 
have a better prognosis than GBMs not containing A Ss.62 
Heterogeneity of metabolic characteristics and of cellu­
lar necrosis in astrocytic tumors30,31 and heterogeneity of 
blood volume in vivo in high-grade astrocytomas5 occur 
on a scale less than 0.1 ml, much smaller than the small­
est ‘H-MR spectroscopy voxel currently feasible (approx­
imately 1 cc). Heterogeneity found over this scale could 
explain why studies using multiple small *H-MR spec­
troscopy voxels localized by two-dimensional chemical 
shift im aging14,15,20,22 have not demonstrated less scatter 
within, or less overlap between, grades of glial tumors 
than our studies and others using single large voxels. 
Combinations of chemical shift imaging using molar 
quantitation3,24*29,35 and short-echo3,12,34,35,46,60 techniques to 
obtain metabolic information heretofore observed only in 
v/fro16,26,45,59,61 or ex y/w?30,31,51 might improve the specifici­
ty of 'H -M R spectroscopy. However, Preul, et a /.,47 have 
been able to overcome the scatter within each metabolic 
peak and distinguish brain tumor subtypes with very high 
specificity by applying a linear discriminant to analyze the 
patterns o f all o f the peak intensities in spectra obtained 
at a long (270 msec) echo time. To achieve this result, 
they studied only untreated cases and selected from two- 
dimensional chemical shift imaging datasets voxels that 
appeared to be most representative of viable tumor.
Some of the previous studies that focused on metabolite 
ratios in vivo in different histopathological grades of astro-
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cytic tumors reported a higher choline/creatine ratio in 
high- compared to low-grade tumors,4,21,43,57,58,61 but three 
found this ratio unchanged11 or reduced14,32 in high grades 
such as GBM compared to intermediate grades such as 
A A. The mean choline/creatine ratio we observed in astro- 
cytic tumors with minimal brain contamination is higher 
than in many previous reports and is similar* to the result 
of Ott and colleagues4* who used a similar 'H-MR spec­
troscopy technique to examine 48 astrocytic tumors and 
minimized contamination by varying voxel size to fit the 
region of solid, apparently viable tumor.
Comparisons between tumors and contralateral brain 
indicated that the higher mean ratios of levels of cholines 
to creatines and the NAA region in AAs and GBMs 
compared to lower grade ASs (Table 3) is caused partly by 
higher concentrations of cholines and partly by lower con­
centrations of creatines and of the NAA region (Fig. 4). 
These results in general are in accord with those obtained 
in surgical specimens assayed biochemically33 or with *H- 
NMR spectroscopy.16’45,61 The lower creatine concentra­
tion in GBMs compared to lower grade astrocytic tumors, 
and the lack of a higher concentration of cholines in 
GBMs compared to low er grade tumors (Fig. 4), were also 
observed in vivo in other studies in which both tumor and 
brain spectra were obtained from the same subjects.11,14,43
The infrequent occurrence of lactate (12% of all glial 
tumors) and the lack of a correlation with histopathologi- 
cal grade agrees with Ott and colleagues,43 who reported a 
definite lactate resonance in only 19% of 75 spectra from 
48 astrocytic tumors. It is possible that both we and Ott 
and colleagues underestimated the incidence of lactate 
because our techniques have a lower sensitivity to lactate 
than to singlet resonances and because in a few cases high 
lipid signals could mask small amounts of lactate. Kugel, 
et cil.,32 reported lactate in nine (41%) of 22 glial tumors, 
but also found that it occurred equally in low- and high- 
grade tumors. Fulham, et a i ,14 reported lactate in 18 
(41%) of 44 glial tumors, occurring with significantly 
higher incidence in higher grades. However, 13 of the 18 
tumors with lactate had been treated, and the lactate was 
generally observed at the site of surgery and in subacute 
radiation necrosis; thus in many cases viable tumor may 
not have been the source of the lactate. Our results do con­
tradict the conclusions o f several previous studies,2,4,8, 
1 5 ,2 0 - 2 2  s o m e  0f  which may have overestimated the inci­
dence of lactate because of their inability to distinguish 
lactate from lipids.
Methylene and methyl signals were described in glial 
tumors studied with *H-MR spectroscopy using short echo 
times,12,46,60 and Tzika and associates60 assigned lipids to 
the spectra of virtually all childhood brain tumors of vari­
ous types and grades. With short echo times, however, 
these signals may also arise from proteins.6 One criterion 
that may be applied to help distinguish protein from lipid 
signals is that the latter, which are from fatty acyl chains, 
should have a relatively high ratio of the intensity of the 
methylene peak at 1.3 ppm  compared to that of the methyl 
peak at 0.9 ppm .31,51 In our cases with lipids (for example, 
Fig. 5 right), this ratio averaged 5.6 (±  2.8 SD), and 
because Hie T2 relaxation times are similar,31 a similar 
ratio should occur at short echo time. By this criterion, 
Tzika and associates60 have greatly overestimated the inci­
dence of lipids in brain tumors and other disorders.
We have demonstrated the presence of mobile lipids in
a significant fraction of astrocytic tumors and defined 
their relation to histopathological grade. These observa­
tions provide a correlation in vivo of the recent documen­
tation of lipids in 'H-NMR spectroscopy studies of intact 
surgical specimens of brain tumors.30,31,51 Kuesel and co­
workers3031 showed that the amount of mobile lipids in 
higher grade astrocytic tumors correlated with the amount 
of microscopic cellular necrosis within the specimen. The 
lipid signals observed by ^ -M R  spectroscopy arise pre­
dominantly from fatty acyl moieties, which are relatively 
mobile and probably no longer confined to membrane 
phospholipids. Their association with cellular necrosis in 
GBMs is probably due to membrane breakdown. Because 
we observed lipids in eight of 22 AAs, which by defini­
tion27 contain little or no necrosis, we suggest that mem­
brane breakdown may precede histologically evident 
necrosis. Indeed, Kuesel, et a i ,30 suggested that the ap­
pearance of mobile lipids in regions of viable tumor indi­
cates metabolic effects of poor perfusion, and neutral lipid 
droplets were detected in the cytoplasm of hypoxic tumor 
cells.13
Large amounts of lipids appear to be specific for AA or 
GBM, but their absence does not rule out AA or GBM, 
However, it is important to note that histopathological 
grading is imperfect in its correlation with prognosis. In 
adults in particular, the clinical course of lower grade 
tumors, more than half of which recur as, or evolve into, 
an aggressive phenotype, is difficult to predict.38 There­
fore, even if !H~MR spectroscopy metabolic characteris­
tics have limited diagnostic accuracy, they may have prog­
nostic significance, as has been found in the case of 
glucose hypermetabolism in PET.1,23,25,44,56 Current issues 
in the management of patients with AS are whether or not 
there is an advantage to gross-total resection and whether 
or not postoperative radiotherapy influences the rate of 
differentiation or relapse.38 A metabolic characteristic that 
independently correlates with malignant behavior couid 
help the clinician to balance the risks and benefits of 
aggressive therapy more accurately. Because microscopic 
necrosis in GBM does correlate with prognosis,9,10,41 it is 
possible that the presence of lipids will also. Moreover, 
Decause the appearance of mobile lipids appeal's to pre­
cede evident necrosis,30 it is possible that their presence in 
AAs will provide a marker for tumors likely to evolve into 
more aggressive behavior. Therefore, the population that 
has been accrued in this trial will be followed over the 
next few years to obtain relapse-free and overall survival 
statistics. This may enable us to determine if the presence 
of lipids or other metabolic characteristics (for example, 
choline concentrations that are above median vs. those 
below median) predicts prognosis independent of his­
topathological grade.
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